Camrelizumab

Camrelizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	PD1
Clinical data
Other names	SHR-1210
ATC code	None;
Identifiers
CAS Number	1798286-48-2 ;
DrugBank	DB14776 ;
UNII	73096E137E ;

Last updated September 12, 2025

Camrelizumab (SHR-1210) (INN ^[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.^[2] PD-1 is programmed cell death protein 1.

The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019^[update], camrelizumab is undergoing Phase II/III trials.

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
↑ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi: 10.1200/JCO.18.02151 . PMID 31039052. S2CID 141482897.{{cite journal}}: CS1 maint: overridden setting (link)

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[WHOList117-1] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).

[2] Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi: 10.1200/JCO.18.02151 . PMID 31039052. S2CID 141482897.{{cite journal}}: CS1 maint: overridden setting (link)

[1]

[2]